You have no items in your shopping cart.

Cart empty

Shop By

Reset All
Listed in Category: Hormonal medication

Amaryl 3 mg 30 tablets

Availability: In Stock



Active ingredients: glimepiride
Manufacturer: aventis
Country of origin: Italy
General description: The oral hypoglycemic medication

Dosage form
glimepiride 3 mg

Excipients: lactose monohydrate, carboximetilkrahmal sodium (type A), povidone 25 000, microcrystalline cellulose, magnesium stearate, colorant iron oxide yellow (E172).
Pharmacological action
Oral hypoglycemic drugs - derived sulfonylureas of the III generation.

Glimepiride reduces the concentration of glucose in the blood, mainly by stimulating insulin release from the beta cells of the pancreas. Its effect is primarily associated with the improved ability of the beta cells of the pancreas to respond to physiological stimulation of glucose. Compared with glibenclamide, glimepiride in low doses causes the release of a smaller quantity of insulin while achieving approximately the same reduction in the concentration of glucose in the blood. This fact testifies in favor of the presence of glimepiride extrapancreatic hypoglycemic effects (increased sensitivity of tissues to insulin and insulinomimetic effect).

The secretion of insulin. Like all other sulfonylureas, glimepiride regulates insulin secretion by interactions with ATP-sensitive potassium channels in the membranes of beta cells. Unlike other derivatives of sulfonylurea glimepiride selectively binds to the protein with molecular weight 65, kilodalton located in the membranes of the beta cells of the pancreas. This interaction of glimepiride with communicating with him protein regulates the opening or closing of ATP-sensitive potassium channels.

Glimepiride closes potassium channels. This causes depolarization of beta cells and leads to opening of voltage-sensitive calcium channels and influx of calcium into the cell. As a result, the increase in intracellular concentration of calcium activates the secretion of insulin through exocytosis.

Glimepiride is much faster and therefore more frequently comes into contact and is released from connection with communicating with him in protein than glibenclamide. It is expected that this property of high exchange rate of glimepiride from communicating with him protein is responsible for its pronounced effect of sensitization of beta cells to glucose and their protection from desensitization and premature exhaustion.

The effect of increasing the sensitivity of tissues to insulin. Glimepiride increases the effects of insulin on glucose uptake by peripheral tissues.

Insulinomimetic effect. Glimepiride has effects similar to the effects of insulin on glucose uptake by peripheral tissues and glucose output from the liver.

Glucose uptake by peripheral tissues is carried out by its transport inside muscle cells and adipocytes. Glimepiride directly increases the number of glucose transport molecules in the plasma membranes of muscle cells and adipocytes. The increase in revenues inside the cells of glucose leads to the activation of glycosylphosphatidylinositol-specific phospholipase C. as a result, intracellular calcium concentration is reduced, causing a decrease in the activity of protein kinase A, which in turn leads to stimulation of glucose metabolism.

Glimepiride inhibits the glucose output from the liver by increasing the concentration of fructose-2,6-bisphosphate, which inhibits gluconeogenesis.

Influence on platelet aggregation and atherosclerotic plaque formation. Glimepiride reduces platelet aggregation in vitro and in vivo. This effect is apparently associated with selective inhibition of COX, which is responsible for the formation of thromboxane A, an important endogenous factor of platelet aggregation.

diabetes type 2 diabetes (as monotherapy or in combination therapy with Metformin or insulin).

To Top
© 2016-2020
All right reserved.